A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk
Hao Zhang,Jie-mei Gu,Ai-jun Chao,Qun Cheng,Dong-hui Teng,Jin-ming Yu,Bing-wu Wang,Ya-nan Huo,Li Mao,Qiu Zhang,Hong Yang,Shi-gui Yan,Ke-qin Zhang,Xue-ling Zhao,Hua Lin,Yu Pei,Zhong Yuan,Ru-chun Dai,Liang He,Li Chen,Yong-feng Su,Zhong-liang Deng,Li You,Bo Ban,Mei Zhu,You-liang Cao,Yi-kun Zhu,Zhi-jun Li,Zhi Zhang,Cheng-qing Yi,Yi-bing Lu,Guang Wang,Cui-cui Han,Zhen-jiang Wang,Xian-xing Li,Zhen-lin Zhang
DOI: https://doi.org/10.1038/s41401-022-00954-y
IF: 7.169
2022-01-01
Acta Pharmacologica Sinica
Abstract:The current study evaluated the efficacy and safety of a denosumab biosimilar, QL1206 (60 mg), compared to placebo in postmenopausal Chinese women with osteoporosis and high fracture risk. At 31 study centers in China, a total of 455 postmenopausal women with osteoporosis and high fracture risk were randomly assigned to receive QL1206 (60 mg subcutaneously every 6 months) or placebo. From baseline to the 12-month follow-up, the participants who received QL1206 showed significantly increased bone mineral density (BMD) values (mean difference and 95% CI) in the lumbar spine: 4.780% (3.880%, 5.681%), total hip :3.930% (3.136%, 4.725%), femoral neck 2.733% (1.877%, 3.589%) and trochanter: 4.058% (2.791%, 5.325%) compared with the participants who received the placebo. In addition, QL1206 injection significantly decreased the serum levels of C-terminal crosslinked telopeptides of type 1 collagen (CTX): −77.352% (−87.080%, −66.844%), and N-terminal procollagen of type l collagen (P1NP): −50.867% (−57.184%, −45.217%) compared with the placebo over the period from baseline to 12 months. No new or unexpected adverse events were observed. We concluded that compared with placebo, QL1206 effectively increased the BMD of the lumbar spine, total hip, femoral neck and trochanter in postmenopausal Chinese women with osteoporosis and rapidly decreased bone turnover markers. This study demonstrated that QL1206 has beneficial effects on postmenopausal Chinese women with osteoporosis and high fracture risk.